ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Review

Multiple system atrophy: genetic risks and alpha-synuclein mutations

[version 1; peer review: 2 approved]
PUBLISHED 30 Nov 2017
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

Multiple system atrophy (MSA) is one of the few neurodegenerative disorders where we have a significant understanding of the clinical and pathological manifestations but where the aetiology remains almost completely unknown. Research to overcome this hurdle is gaining momentum through international research collaboration and a series of genetic and molecular discoveries in the last few years, which have advanced our knowledge of this rare synucleinopathy. In MSA, the discovery of α-synuclein pathology and glial cytoplasmic inclusions remain the most significant findings. Families with certain types of α-synuclein mutations develop diseases that mimic MSA, and the spectrum of clinical and pathological features in these families suggests a spectrum of severity, from late-onset Parkinson’s disease to MSA. Nonetheless, controversies persist, such as the role of common α-synuclein variants in MSA and whether this disorder shares a common mechanism of spreading pathology with other protein misfolding neurodegenerative diseases. Here, we review these issues, specifically focusing on α-synuclein mutations.

Keywords

multiple system atrophy, MSA, neurodegenerative disorders, α-synuclein

Introduction

Multiple system atrophy (MSA) is a neurodegenerative movement disorder affecting around 1 in 20,000 people1,2. It occurs sporadically, usually presenting between the age of 35 and 65 years with a variable combination of parkinsonian, cerebellar, and autonomic features and rapidly progressing for 9 years on average36. According to the presenting clinical features and predominant manifestations, MSA is usually categorised as MSA-C or MSA-P, there can be mixed signs, and some patients present with autonomic features. Familial MSA has been reported but in only a handful of cases worldwide. Research toward potential treatments for MSA, as with many rare diseases, has been limited, resulting in a paucity of knowledge regarding its underlying causes. Initial clues came from studying α-synuclein (SNCA) and the hallmark histopathology in the brains of patients with MSA: glial cytoplasmic inclusions (GCIs) that reside predominantly in oligodendrocytes, the post mortem identification of which is required for a definitive diagnosis. Besides MSA, the only conditions that have GCIs in the brain are certain families with SNCA mutations. Three groups found that the GCIs contain abnormal forms of SNCA protein712, the same protein that accumulates in Parkinson’s disease (PD) and dementia with Lewy bodies12. These studies were motivated by a link between point mutations in the SNCA gene and heritable forms of PD13,14. The similarities between MSA and PD have proven more complicated to disentangle, as SNCA mutations in some families clinically and pathologically resemble MSA and others even have features of frontal dementia with severe pathology15.

It has been nearly two decades since MSA was characterised as a synucleinopathy, and apart from the PD-MSA overlap identified in SNCA families, researchers have not been able to further understand the aetiology of MSA or alter or halt the disease process. This brief review will set out the progress that has been made in recent years toward understanding the pathomechanisms of SNCA aggregation and toxicity in relation to MSA, particularly the emerging hypotheses of aetiology based on genetic studies. As clinical trials targeting SNCA proceed in PD and MSA, there is increasing urgency to better understand its relevant cellular interactions in parallel with the development of sensitive biomarkers capable of diagnosing patients at an earlier disease stage.

The role of α-synuclein in multiple system atrophy

Despite the key involvement of abnormal SNCA processing, misfolding, and aggregation in synucleinopathies, the normal function of the protein is not fully understood. It is a peripheral membrane protein, localized at nerve terminals where it is thought to play a role in the release of neurotransmitters, and recently has been reported to enhance transient synaptic vesicle fusion16,17 and possibly disrupt the support and maintenance of neurons provided by oligodendrocytes. In MSA, SNCA is deposited widely, but there are more severely affected regions such as the basal ganglia, cerebellum, pons, inferior olivary nuclei, and spinal cord18,19. Not only is SNCA deposition clearly distinguishable between MSA and PD cases but MSA-like pathology underlies both cerebellar (MSA-C) and parkinsonian (MSA-P) manifestations. There is also minimal change MSA pathology in some cases that have a longer disease duration. How this single protein can apparently be the culprit in these different disease phenotypes, with such varied localization in different cell types and brain regions, is an unresolved question.

One compelling explanation for the clinicopathological diversity in the synucleinopathies is that distinct strains of SNCA are responsible for generating heterogeneity20. These conformational variants include different oligomer combinations, fibrils and ribbons, although their relative contribution to the anatomical distribution and deposition of SNCA in MSA and other synucleinopathies and the formation of GCIs in MSA has yet to be determined. Furthermore, it has been posited that the specific structure of SNCA derived from inclusions in the brains of patients with MSA is especially toxic, capable of propagating to adjacent cells and inducing neurodegeneration when injected into transgenic mice, akin to the permissive templating of prion protein and even prompting reclassification of MSA as a prion disease21,22. However, it remains to be shown conclusively that oligodendroglial MSA-type pathology is provoked by seeded aggregation of SNCA.

The pathomechanisms of MSA are being steadily elucidated as studies examine the molecular interactions of SNCA with other proteins in MSA. A recent study23 has reported that SNCA engages with proteins that regulate autophagy in the MSA brain, implicating cellular degradation as central to the pathogenesis of MSA and potentially unifying it with other neurodegenerative diseases for the purpose of therapeutic intervention of these pathways23,24. Additionally, there is an emerging conviction that SNCA induces deficits in myelination25 and there is a possible role for inflammatory/apoptotic mechanisms.

Mutations and copy number variation in α-synuclein

The initial genome-wide association study (GWAS) in PD yielded significant association at the SNCA and microtubule-associated protein tau (MAPT) genes26. Common variation in the gene encoding SNCA was first identified as a risk factor for MSA in 200927, but the association of variants across SNCA in different populations was not replicated in later studies2832 and was thought to be due to a mixed control population used in the initial studies. The first GWAS to be conducted in MSA yielded negative results around the SNCA locus28. As mentioned earlier, several SNCA point mutations14,3339 and SNCA gene duplications40, triplications41,42, and double duplications43 have been associated with familial forms of PD (Figure 1 and Table 1 and Table 2). Some of these families have manifestations of both PD and MSA and have clinical signs or neuropathological features or both44,45. In particular, the A53T, A53E, and G51D mutations and SNCA gene triplications are associated with a more aggressive MSA-like clinical and pathological phenotype45 (See Table 1 and Table 2 for details of the clinical and neuropathological features of SNCA mutations). Exactly why the codon 51 and 53 mutations in the SNCA gene lead to an MSA-like clinical and pathological phenotype is not known, but this is likely to be associated with the importance of this defined region and toxic gain of function of these protein changes (Figure 1)46. From a clinical perspective, if there is any hint of a family history in patients with MSA, then the SNCA gene should be sequenced by using traditional Sanger47, gene panel, or exome sequencing and analysed for copy number changes48.

a7b2a7d1-9c6b-4eba-bd3d-a6fe178edf86_figure1.gif

Figure 1. Structural features of the alpha-synuclein monomer.

A structure of the full-length, membrane-bound form of alpha-synuclein (SNCA) protein reveals a conformation in which the N-terminal two-thirds of the protein forms a broken, amphipathic alpha-helix. This structured portion of the protein is responsible for membrane binding, and residues at the very N-terminus are essential for this process. In the nuclear magnetic resonance structure of SNCA, the negatively charged C-terminal tail remains flexible and disordered (based on Yu et al.46). The positions of point mutations associated with Parkinson’s disease are indicated with arrows and in pink. All mutations are heterozygous, except for p.A53V, which is homozygous.

Table 1. Clinical features of families with alpha-synuclein (SNCA) mutations.

SNCA
protein
change
p.Ala30Pro1p.Glu46Lys2p.His50Gln3p.Gly51Asp4,5p.Ala53Thr6p.Ala53Glu7p.Ala53Val8Duplication9Triplication10Double
duplication11
SNCA: 5′
start - ATG
start -
177G>C
c.88G>C
225G>A
c.136G>A
239T>G
c.150T>G12
241G>A
c.152 G>A
246G>A
c.157G>A
247C>A
c.158C>A
247C>T
c.158C>T
Whole gene
copy number
Whole gene
copy number
Whole gene
copy number
ZygosityHeterozygousHeterozygousHeterozygousHeterozygousHeterozygousHeterozygousHomozygous/
heterozygous
Gene
duplication on
one allele
Gene
triplication on
one allele
Gene
duplication
on both
alleles
Clinical
phenotype
Classic PDDementia with
Lewy bodies
phenotype
Classic PDSevere PD with
some patients
with MSA
features
Severe PD with
some patients
with MSA
features
Severe PD with
some patients
with MSA
features
Homozygous
= PD
Heterozygous
= cognitive
decline or
psychosis
Usually classic
PD, some
with severe
cognitive
and frontal
dementia13
Severe PD
with some
patients with
MSA features
Severe PD
FamilyGerman14Spanish Basque
Country15
English16British4,
French17, and
Japanese18
Large Sicilian
(Contursi)
kindred6
and Greek19,
Swedish20,
Korean21
Finnish22Japanese23French24,
Italian25,
Japanese26,27,
Korean28,
Swedish29, UK,
Welsh13
Spellman-
Muenter
(Iowa)
kindred30,
Swedish9
Pakistani31
Estimated
penetrance/
risk
71.4%30%30%
Heterozygous
ExAc
=4/121,306
100%85%100%Homozygous
100%
Heterozygous
on ExAc =
1/121,304
44%27100%100%
Mean age of
onset, years
6050–657144 (as early as 19)5484359504031
Clinical
symptoms
Progressive
parkinsonism,
walking
difficulties,
no other
non-motor
symptoms
except
cognitive
decline (50%
of patients)
Resting tremor,
bradykinesia,
postural
instability,
severe
immobility,
dementia,
and visual
hallucinations
Resting hand
tremor, benign
course
Resting tremor,
dystonia,
cognitive/frontal
decline, anxiety,
depression,
visual
hallucination,
and autonomic
disturbances5
Moderate
tremor, rigidity,
bradykinesia,
postural
instability,
severe
dementia,
depression,
and autonomic
disturbance32
Bradykinesia,
resting tremor,
rigidity,
insomnia,
spasticity,
myoclonic
jerks, anxiety,
and panic
disorders
Bradykinesia,
resting tremor,
rigidity, mild
cognitive
decline, visual
hallucination,
sleep
disorder,
delusions,
and paranoia
Bradykinesia,
resting tremor,
rigidity, mild
asymmetric
onset. Some
have epilepsy,
depression,
and frontal
dementia.
Severe
early onset
parkinsonism,
resting tremor,
bradykinesia,
rigidity, and
symptoms of
MSA
Severe
bilateral
bradykinesia
rigidity,
mild resting
tremor,
severe
depression,
and
postpartum
psychosis
Sustained
response to
levodopa
Transient
marked,
developed
hallucinations
Mild to
moderate,
developed
hallucinations
and conscious
fluctuation
ModerateTransient
marked,
developed
choreiform
movements
MarkedMarked,
developed
dyskinesia33
MarkedMild to
moderate,
developed
motor
fluctuation and
dyskinesia
MarkedN/A

ExAC, http://exac.broadinstitute.org; MSA, multiple system atrophy; N/A, no data available; PD, Parkinson’s disease; SNCA, alpha-synuclein gene.

Table 2. Neuropathological features of families with alpha-synuclein (SNCA) mutations.

SNCA protein changep.Ala30Pro1p.Glu46Lys2p.His50Gln3p.Gly51Asp4,5p.Ala53Thr6,34p.Ala53Glu7Duplication35Triplication10
Neuropathology
summary
Widespread
synuclein
neuropathology
and LBs
Widespread
synuclein
and ubiquitin
neuropathology
and LBs
Widespread
synuclein
neuropathology
and LBs
Widespread
synuclein
neuropathology,
LBs, and GCIs
Widespread
synuclein
neuropathology,
LBs, and GCIs
Widespread
synuclein
neuropathology,
LBs, and GCIs
Widespread
synuclein
neuropathology,
LBs, and some
GCIs
Widespread
synuclein
neuropathology,
LBs, and GCIs
LBsYesYesYesYesYesYesYesYes
Cortical neuronal lossWidespreadWidespreadNot identifiedWidespread,
moderate to
severe, anterior
temporal,
piriform, and
insular cortices4
Widespread,
moderate to
severe, mid-
frontal cortex,
superior temporal
cortex, and
inferior parietal
cortex
Widespread and
severe
Not identifiedWidespread
Hippocampal neuronal
loss
CA1/2/3Not identifiedNot identifiedSevere in CA2/34Severe in CA1,
moderate in
CA2/334
Mild in CA1/2/3CA2/3 regionCA2/3 region
Brain stem neuronal
loss
Substantia
nigra, locus
coeruleus, and
dorsal nuclei of
the vagus
Substantia
nigra, locus
coeruleus, and
dorsal nuclei of
the vagus
Substantia nigraSubstantia nigra,
locus coeruleus,
and dorsal motor
nuclei of vagus
Substantia
nigra and locus
coeruleus
Substantia nigraSubstantia nigra,
locus coeruleus,
and dorsal motor
nuclei of vagus
Substantia
nigra and locus
coeruleus
Neuronal α-synuclein
pathology
Globular,
spherical,
reniform,
widespread
om cortex and
brainstem
Concentric,
nonconcentric,
granular
PD-type (Braak
stage 6)
Annular,
crescentic,
globular,
diffuse, NFT-like,
Widespread
cortical
Wide spread
cortex and brain
stem, LBs
Annular, annular,
LB-like inclusions,
mild in brainstem
PD-type (Braak
stage 6),
widespread from
brainstem and
neocortex
Widespread in
cortex, few in
brainstem
Glial α-synuclein
pathology
NoNoNoGCI-likeGCI-likeGranular GCIGCI-likeAtypical LBs, GCIs
Phosphorylated tau
Braak and Braak stage
IINot identifiedIIIIIaIN/AI N/A
Aβ depositionThal phase 136 NeocorticalNeocorticalN/AN/AN/ASparse neocortical N/A

There has been no neuropathology on the p.Ala53Val mutation, and the double duplication has no brain donation. GCI, glial cytoplasmic inclusions; LB, Lewy body; N/A, no data available; NFT, neurofibrillary tangle; PD, Parkinson’s disease.

Other genetic risk factors for multiple system atrophy

A number of PD risk factors have not been replicated in MSA4,6,4861, but other disorders such as spinocerebellar ataxia type 17 and progressive supranuclear palsy6264 can mimic MSA in the early stages and should be included in clinical and genetic testing. In a statistical analysis of 5,302 patients with PD and 4,161 controls from 15 sites, Elbaz and colleagues found no evidence for an interactive effect between the H1 haplotype in the MAPT gene and single-nucleotide polymorphisms in the SNCA gene on disease65. Variation in each gene was associated with PD risk, indicating independent effects. In MSA, the H1 haplotype has been associated with MSA66 and the MAPT gene was also implicated in the MSA GWAS28. Familial inheritance of MSA is rare but has been observed. These families often have atypical clinical features, and the genetic analysis led to the discovery of mutations in the COQ2 gene, which plays a role in synthesising the mitochondrial electron transporter and antioxidant coenzyme Q10. These mutations were posited to impair the activity of the mitochondrial respiratory chain and increase oxidative stress, implicating COQ2 variants as a risk factor for sporadic MSA58. Though initially promising, these findings have not been consistently replicated in various populations, refuting COQ2 polymorphisms as common MSA risk factors58. Nonetheless, this has turned attention, and emerging hypotheses centre on mitochondrial dysfunction as a central component of the pathophysiological cascade in MSA67.

The first GWAS in MSA was carried out by Sailer and colleagues and was extremely important but challenging given the rarity of MSA28. At just under 1,000 MSA cases, the analysis was still statistically under-powered28. Studies that are more highly powered are needed to follow up on the importance of the three genes identified that were flagged for being associated: FBXO47, ELOVL7, and MAPT28. It will be important to follow this GWAS up with greater numbers of MSA cases, analyse age at onset association6870, and employ advanced transcriptome sequencing in MSA patient brain tissue to assess the associated genes and other genes thought to be involved in MSA, such as immune-responsive and iron metabolism genes71,72.

Clinical genetic testing and translation

Accurate and early diagnosis of MSA continues to be an important research objective as the heterogeneous features of PD and other atypical parkinsonism syndromes can mimic MSA. One retrospective clinicopathological study revealed that 38% of patients were misdiagnosed with MSA on the basis of expert interpretation of their symptomatic presentation7375. Genetic analysis will be important to identify the rare MSA cases with SNCA mutations and to help differentiate MSA from similar disorders such as spinocerebellar ataxia type 1762,64. Thus, biomarkers that are more sensitive are imperative to improve diagnosis and enlist individuals with the appropriate disease in clinical trials. This will be imperative in the development of effective treatments for the MSA patient population. Both α-synuclein and CoQ10 are being pursued as potential therapeutic targets, and international collaborative study groups are promoting this work with CoQ10 supplementation, the preparation of α-synuclein antisense oligonucleotide, and immunisation trials to be conducted in PD and MSA patients by either intravenous or intrathecal routes.

Until disease-modifying treatments become available, symptom management will remain the mainstay of care for patients with MSA. Patient support organisations such as the MSA Trust (www.msatrust.org.uk/) and the MSA coalition (https://www.multiplesystematrophy.org/) and their clinical nurse specialists are essential in providing support and advice on patient care in this rare disorder. The established drugs for controlling parkinsonism, such as L-dopa, can be effective in the early stages of MSA but often worsen the symptoms due to hypotension later in the disease. A rational treatment, based on the pathophysiology of MSA and perhaps repurposed from PD trials, needs to be developed to offer patients with MSA hope for this devastating disorder.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 30 Nov 2017
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Whittaker HT, Qui Y, Bettencourt C and Houlden H. Multiple system atrophy: genetic risks and alpha-synuclein mutations [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):2072 (https://doi.org/10.12688/f1000research.12193.1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 30 Nov 2017
Views
0
Cite
Reviewer Report 30 Nov 2017
Dean Pountney, School of Medical Science, Griffith University, Queensland, Australia 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Pountney D. Reviewer Report For: Multiple system atrophy: genetic risks and alpha-synuclein mutations [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):2072 (https://doi.org/10.5256/f1000research.13198.r28272)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
0
Cite
Reviewer Report 30 Nov 2017
Mathias Toft, Department of Neurology, Oslo University Hospital, Oslo, Norway 
Approved
VIEWS 0
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Toft M. Reviewer Report For: Multiple system atrophy: genetic risks and alpha-synuclein mutations [version 1; peer review: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):2072 (https://doi.org/10.5256/f1000research.13198.r28273)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 30 Nov 2017
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.